UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brain network segregation and integration during an epoch-related working memory fMRI experiment

NeuroImage (Orlando, Fla.), 2018-09, Vol.178, p.147-161

2018

Volltextzugriff (PDF)

Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse

Annals of oncology, 2024-10

2024

Volltextzugriff (PDF)

Memory-reliant Post-error Slowing Is Associated with Successful Learning and Fronto-occipital Activity

Journal of cognitive neuroscience, 2016-10, Vol.28 (10), p.1539-1552

2016

Volltextzugriff (PDF)

The Sustained Influence of an Error on Future Decision-Making

Frontiers in psychology, 2017-06, Vol.8, p.1077-1077

2017

Volltextzugriff (PDF)

Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias

Supportive care in cancer, 2021-04, Vol.29 (4), p.1883-1891

2021

Volltextzugriff (PDF)

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study

ESMO open, 2023-06, Vol.8 (3), p.101569-101569, Article 101569

2023

Volltextzugriff (PDF)

Assessment of Karnofsky performance scores in brain tumour patients: the role of clinician bias

Supportive care in cancer, 2021-04, Vol.29 (4), p.1883

2021

Volltextzugriff (PDF)

PH-0271 Mid-p strategy versus ITV strategy in locally advanced lung cancer. A randomized phase II study

Radiotherapy and oncology, 2021-08, Vol.161, p.S180-S181

2021

Volltextzugriff (PDF)

VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Annals of oncology, 2024-06, Vol.35 (6), p.576-577

2024

Volltextzugriff (PDF)

LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial

Annals of oncology, 2023-10, Vol.34, p.S1261-S1261

2023

Volltextzugriff (PDF)

480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)

Annals of oncology, 2022-09, Vol.33, p.S759

2022

Volltextzugriff (PDF)

P05.28 Karnofsky performance score of brain tumor patients depends on clinician status

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii309-iii309

2018

Volltextzugriff (PDF)

OS3.4 Karnofsky and WHO performance scores of brain tumour patients may limit inclusion in protocols though they depend on clinician status

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii9-iii9

2019

Volltextzugriff (PDF)

LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

Annals of oncology, 2021-09, Vol.32, p.S1335-S1335

2021

Volltextzugriff (PDF)

LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Annals of oncology, 2020-09, Vol.31, p.S1199-S1199

2020

Volltextzugriff (PDF)

The readability of scientific texts is decreasing over time

eLife, 2017-09, Vol.6

2017

Volltextzugriff (PDF)

LBA88Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Annals of oncology, 2019-10, Vol.30, p.v926-v927

2019

Volltextzugriff (PDF)

260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A216-A217

2021

Volltextzugriff (PDF)

A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

Therapie von Hand- und Fußekzemen unter stationären Bedingungen

Aktuelle Dermatologie, 2007-10, Vol.33 (10), p.379-384

2007

Volltextzugriff (PDF)

Examining new remedy for the cobalt blues

American metal market, 1996-01, Vol.104, p.7A-8A

Schiffler, C

1996

Volltextzugriff (PDF)

DESMEX: A novel system development for semi-airborne electromagnetic exploration

Geophysics, 2020-11, Vol.85 (6), p.E253-E267

2020

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Brain network segregation and integration during an epoch-related working memory fMRI experiment

Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse

Memory-reliant Post-error Slowing Is Associated with Successful Learning and Fronto-occipital Activity

The Sustained Influence of an Error on Future Decision-Making

Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study

Assessment of Karnofsky performance scores in brain tumour patients: the role of clinician bias

PH-0271 Mid-p strategy versus ITV strategy in locally advanced lung cancer. A randomized phase II study

VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial

480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)

P05.28 Karnofsky performance score of brain tumor patients depends on clinician status

OS3.4 Karnofsky and WHO performance scores of brain tumour patients may limit inclusion in protocols though they depend on clinician status

LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

The readability of scientific texts is decreasing over time

LBA88Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

LBA88 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER

260 Impact of BRCA & PD-L1 in EOC patients receiving standard 1st line therapy +/- Pembrolizumab: Exploratory analyses from the NeoPembrOV Study (GINECO)

A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Therapie von Hand- und Fußekzemen unter stationären Bedingungen

Examining new remedy for the cobalt blues

DESMEX: A novel system development for semi-airborne electromagnetic exploration

Suchergebnisse filtern